Bedrijfsoverzicht
Mainz Biomed N.V. is a specialized enterprise focused on the development and commercialization of in-vitro diagnostic tests designed for the early detection of cancer within the United States and European markets. The company operates within the healthcare sector, specifically targeting the diagnostics and research industry, where it provides critical molecular genetic solutions for colorectal and pancreatic cancer screening. As of the latest reporting period, the company holds a market capitalization of $5.54M and generated annual revenue of $537,080, while the specific employee count is listed as not available in the provided data. These valuation and revenue figures indicate that Mainz Biomed operates as a small-cap entity with a relatively modest revenue base, suggesting it is in a phase where product development and market penetration are primary operational drivers rather than mature commercial scaling. The lack of detailed employee data further characterizes the company's current scale as limited, typical for biotech firms in the research and development stage that prioritize intellectual property generation over large-scale workforce expansion.
Financiële gezondheid
The company reported revenue of $537,080 over the trailing twelve months, yet recorded a net income of $-16,210,718 and an EBITDA of $-12,883,098, revealing a significant disparity between top-line sales and bottom-line profitability. This substantial gap between revenue and net income highlights an extremely aggressive cost structure where operating expenses far exceed the generated income, a common characteristic in early-stage biotechnology companies but one that demands rigorous cost control. Mainz Biomed generated free cash flow of $-7,107,252, which indicates a negative cash generation scenario that limits the company's immediate financial flexibility and reliance on external capital sources to fund ongoing operations and research initiatives. The financial margins reflect this operational challenge, with a gross margin of 72.6% indicating efficient production costs relative to sales, contrasted sharply by an operating margin of -2159.9% and a profit margin of 0.0% that underscore the heavy burden of overhead and development costs. Regarding solvency, the company maintains cash reserves of $889,091 against total debt of $2.57M, resulting in a debt-to-equity ratio of 400.80 that signifies a highly leveraged balance sheet relative to its equity base. Liquidity is further constrained by a current ratio of 0.50, which indicates that the company's current assets are insufficient to cover its current liabilities without additional financing or asset liquidation. Finally, the return metrics show a return on equity of -488.3% and a return on assets of -89.6%, revealing that management has not yet achieved positive capital efficiency and that the company is currently destroying shareholder value relative to its invested capital.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are both listed as N/A due to the company's lack of positive earnings, which implies that traditional earnings-based valuation models cannot be applied and that investors must rely on alternative metrics to assess the asset. The price-to-book ratio stands at 0.72, suggesting that the market values the company at a discount to its net asset book value, potentially reflecting skepticism regarding the recoverability of those assets or the ability of the company to convert them into future cash flows. Alternative valuation multiples such as the price-to-sales ratio of 10.32 and an EV/EBITDA of -0.56 provide a different perspective, indicating that while the company trades at a premium relative to its sales, the negative EV/EBITDA underscores the inability to service debt with current operating earnings. Historical price volatility is contextualized by a 52-week high of $4.43 and a 52-week low of $0.40, with the current market price positioned significantly below the recent peak, reflecting the uncertainty surrounding the company's path to profitability. The beta value of 0.47 indicates that the stock's price volatility is substantially lower than the broader market, suggesting that the share price is less sensitive to general market movements but carries specific idiosyncratic risks related to its development pipeline.
Growth & Income
Revenue growth year-over-year is recorded at -32.9%, while earnings growth is N/A due to the absence of positive earnings, indicating that the company is currently contracting in terms of sales rather than expanding its market share. Since the company is not a dividend payer, the dividend yield and payout ratio are both N/A or 0.0%, meaning that no cash is distributed to shareholders and all available capital must be reinvested into research, development, and operational expenses to attempt to reverse the revenue contraction. The overall growth and income profile is defined by negative revenue momentum and a complete lack of current income generation, requiring the company to secure additional funding to sustain its development efforts and achieve the financial milestones necessary for a sustainable valuation.